Who are anti-pseudomonal penicillin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-pseudomonal-penicillin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

anti-pseudomonal penicillin — Competitive Intelligence Brief

anti-pseudomonal penicillin (anti-pseudomonal penicillin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic (anti-pseudomonal penicillin). Area: Infectious Disease.

marketed Beta-lactam antibiotic (anti-pseudomonal penicillin) Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

anti-pseudomonal penicillin (anti-pseudomonal penicillin) — Vanderbilt University Medical Center. Anti-pseudomonal penicillins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing cross-linking of peptidoglycan, with enhanced activity against Pseudomonas aeruginosa compared to standard penicillins.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
anti-pseudomonal penicillin TARGET	anti-pseudomonal penicillin	Vanderbilt University Medical Center	marketed	Beta-lactam antibiotic (anti-pseudomonal penicillin)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic (anti-pseudomonal penicillin) class)

Vanderbilt University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). anti-pseudomonal penicillin — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-pseudomonal-penicillin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab